๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

โœ Scribed by Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel

Publisher
Springer US
Year
1984
Tongue
English
Weight
239 KB
Volume
2
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

๐Ÿ“œ SIMILAR VOLUMES

A phase II trial of promace-cytabom in p
A phase II trial of promace-cytabom in previously untreated non-hodgkin's lymphoma of intermediate- or high-grade histology
โœ G. Rossi; M. R. Mariano; G. Arcangeli; V. Bonfanti; M. A. Capucci; P. Ferremi; P ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 560 KB

the aggressive combination chemotherapy programme ProMACE-CytaBOM was used at a community-based hospital as primary treatment for non-Hodgkin's lymphoma (NHL) of intermediate or high-grade histology in Ann-Arbor stages IB-IV. The 53 patients entering the study represented 90 per cent of all consecut

Long-term follow-up of patients receivin
Long-term follow-up of patients receiving salvage chemotherapy for intermediate and high grade non-Hodgkin's lymphomas
โœ Dr. Raymond H. S. Liang; Edmond K. W. Chiu; T. K. Chan; David Todd; Ronald P. Ng ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 423 KB ๐Ÿ‘ 1 views

This is an analysis of the long-term follow-up data of 99 patients receiving HOAP-Bleo, IMVP-16 and PAC as salvage chemotherapy for refractory or relapsed intermediate or high grade non-Hodgkin's lymphomas. Most of the patients received HOAP-Bleo or PAC following failure of initial chemotherapy and

A randomized trial of two types of adjuv
A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma
โœ J. Wagstaff; I. Todd; D. Deakin; P. Wilkinson; J. H. Scarffe; M. Harris; M. Jone ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 600 KB

This paper reports the 8-year results of comparing the use of two types of adjuvant chemotherapy following involved field radiotherapy for clinical stages I and II high-grade non-Hodgkin's lymphoma. Twenty-four patients received 6 weeks of VAP plus 2 years of oral maintenance chemotherapy, and 30 ha